{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:06:13Z","timestamp":1779887173445,"version":"3.53.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41571-026-01153-y","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:34:34Z","timestamp":1776857674000},"page":"399-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic induction therapy and the expanding frontier of bladder preservation in MIBC"],"prefix":"10.1038","volume":"23","author":[{"given":"Laura S.","family":"Mertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1153_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"1153_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04271-3","author":"JJ Mellema","year":"2026","unstructured":"Mellema, J. J. et al. Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04271-3 (2026).","journal-title":"Nat. Med."},{"key":"1153_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","volume":"27","author":"A Necchi","year":"2026","unstructured":"Necchi, A. et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 27, 442\u2013451 (2026).","journal-title":"Lancet Oncol."},{"key":"1153_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839\u20131844 (2020).","journal-title":"Nat. Med."},{"key":"1153_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. 394, 1257\u20131269 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1153_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","volume":"87","author":"A Masson-Lecomte","year":"2025","unstructured":"Masson-Lecomte, A. et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update. Eur. Urol. 87, 697\u2013716 (2025).","journal-title":"Eur. Urol."},{"key":"1153_CR7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/1078-0432.CCR-25-3712","volume":"32","author":"IB Epstein","year":"2026","unstructured":"Epstein, I. B. et al. ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer. Clin. Cancer Res. 32, 1522\u20131527 (2026).","journal-title":"Clin. Cancer Res."},{"key":"1153_CR8","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1200\/JCO-25-01608","volume":"43","author":"A Necchi","year":"2025","unstructured":"Necchi, A. et al. End points for the next-generation bladder-sparing perioperative trials for patients with muscle-invasive bladder cancer. J. Clin. Oncol. 43, 3536\u20133544 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1153_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1200\/JCO-25-01324","volume":"44","author":"JL Gore","year":"2026","unstructured":"Gore, J. L. et al. Twelve-month results from the CISTO study comparing radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle-invasive bladder cancer. J. Clin. Oncol. 44, 274\u2013285 (2026).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01153-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01153-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:02:12Z","timestamp":1779883332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01153-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01153-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"22 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.S.M. reports that her institution has received consulting fees from Johnson & Johnson and Merck. A.M.K. has received research funding from Arquer Diagnostics, EnGene, FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen and SWOG; has acted as advisor or consultant for Astellas Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, Urogen Pharma, US Biotest, Valar Labs and Vivet Therapeutics; holds a joint patent with the MD Anderson Cancer Center for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); and has had leadership roles in the International Bladder Cancer Group (IBCG), European Urology Oncology, the Journal of Urology, UroToday, American Urological Association (AUA) and the World Bladder Cancer Patient Coalition.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}